Recombinant Mouse CXCL3 protein (mFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

mFc Tag

Activity

not tested

Cat no : Eg3868

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse CXCL3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse CXCL3 protein Ala28-Ser100 (Accession# Q6W5C0) with a mouse IgG Fc tag at the C-terminus.
• GeneID: 330122
• Accession: Q6W5C0
• PredictedSize: 34.5 kDa
• SDS-PAGE: 35-40 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells.This chemokine is secreted by a variety of cell types including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, and various tumor cell lines in response to inflammatory stimuli.CXC chemokine ligand 3 (CXCL3) is a member of CXC-type chemokine family that is identified as a major regulator in immune and inflammation responses. CXCL3 is broadly expressed in various human tumor types, and it is also known to play a critical role in mediating tumor development and progression.

References:

1. Adams DH, et al. (1997). Lancet.15;349(9050):490-5.
2. Bonecchi R, et al. (2009). Front Biosci (Landmark Ed).1;14(2):540-51.
3. Cheng Y, et al. (2023). BMC Cancer. 29;23(1):1162.